Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

LB PHARMACEUTICALS INC Director's Dealing 2025

Sep 11, 2025

33183_dirs_2025-09-10_aba20559-1ba3-46c1-b29a-5e6eb06aac81.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: LB PHARMACEUTICALS INC (LBRX)
CIK: 0001691082
Period of Report: 2025-09-10

Reporting Person: Garland J. Scott (N/A)

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (Right to Buy) $41.84 2034-03-03 Common Stock (17929) Direct
Stock Option (Right to Buy) $41.84 2034-06-05 Common Stock (3585) Direct

Footnotes

F1: One fourth (1/4) of the shares subject to the option award vested on March 4, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

F2: One fourth (1/4) of the shares subject to the option award vested on January 31, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.